Biochemistry: Investigation Observed Value Unit Biological Reference Interval

Name : Mr.
ASHUTOSH KUMAR
PID No. : IND97503 Register On : 31/12/2020 9:36 AM
SID No. : 420078189 Collection On : 31/12/2020 10:31 AM
Age / Sex : 43 Year(s) / Male Report On : 31/12/2020 7:01 PM
Type : OP Printed On : 31/12/2020 7:08 PM
MC-3113
Ref. Dr : DR. SELF
Investigation Observed Value Unit Biological Reference Interval

BIOCHEMISTRY
Glucose Fasting (FBS) 231 mg/dL Normal: <= 100

(Plasma - F/GOD- POD) Pre Diabetic: 100 - 125
Diabetic: >= 126
INTERPRETATION: Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence
blood glucose level.
Glucose Postprandial (PPBS) 311 mg/dL < 140
(Plasma - PP/GOD - POD)
INTERPRETATION: Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence
blood glucose level. Fasting blood glucose level may be higher than Postprandial glucose, because of physiological surge in Postprandial
Insulin secretion, Insulin resistance, Dawn Phenomenon, Somogyi Phenomenon, Anti- diabetic medication during treatment for Diabetes.
Urea 15 mg/dL 15 - 45
(Serum/Urease-GLDH/UV)
INTERPRETATION: About 85% of urea is eliminated via kidneys; the rest is excreted via the gastrointestinal (GI) tract. Serum urea is
increased when renal clearance decreased (in acute and chronic renal failure/impairment). Urea may also increase in other conditions not
related to renal diseases such as upper GI bleeding, dehydration, catabolic states, and high protein diets. Urea may be decreased in starvation,
low-protein diet, and severe liver disease.
Creatinine 0.9 mg/dL 0.9 - 1.3
(Serum/Modified Jaffe)
2 0 6
APPROVED BY
* Represent Those Tests are not in scope of NABL accreditation.

NABL Test Done in Accredited lab,MEDALL HEALTHCARE PVT LTD,INDIRANAGAR,,BANGALORE.
Certificate No.MC-3113 * Represent Those Tests are not in scope of NABL accreditation.
NABL Test Done in Accredited lab,CLUMAX DIAGNOSTIC & RESEARCH CENTRE PVT
LTD.,JAYANAGAR,BENGALURU. Certificate No.MC-2271
The results pertain to sample tested. Page 1 of 14
Name : Mr. ASHUTOSH KUMAR
MC-3113
Ref. Dr : DR. SELF

INTERPRETATION: Elevated Creatinine values are encountered in increased muscle mass, severe dehydration, Pre-eclampsia, increased
ingestion of cooked meat, consuming Protein/ Creatine supplements, Diabetic Ketoacidosis, prolonged fasting, renal dysfunction and drugs
such as cefoxitin ,cefazolin, ACE inhibitors ,angiotensin II receptor antagonists,N-acetylcyteine , chemotherapeutic agent such as flucytosine
etc.
Uric Acid 4.6 mg/dL 3.5 - 7.2
(Serum/Uricase/Peroxidase)
Calcium 9.7 mg/dL 8.8 - 10.6
(Serum/Arsenazo III)
2 0 6
APPROVED BY

MC-3113
Ref. Dr : DR. SELF

IMMUNOASSAY
TSH (Thyroid Stimulating Hormone) 4.19 µIU/mL 0.35 - 4.94

(Serum/CMIA)
INTERPRETATION: Detection Limit: 0.0025 - 100 Reference range for cord blood - upto 20
1 st trimester: 0.1-2.5
2 nd trimester 0.2-3.0
3 rd trimester : 0.3-3.0
(Indian Thyroid Society Guidelines)
TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration,race, Ethnicity and BMI.
Prostate specific antigen - Total(PSA) 0.76 ng/mL Normal: 0.0 - 4.0
(Serum/Chemiluminescent Microparticle Inflammatory & Non Malignant
Immunoassay(CMIA)) conditions of Prostate : 4.01 - 10.0
Suspicious of Malignant disease of
Prostate: > 10.0
INTERPRETATION: Analytical sensitivity: 0.008 - 100 ng/mL

PSA is a tumor marker for screening of prostate cancer. Increased levels of PSA are associated with prostate cancer and benign conditions like
bacterial infection, inflammation of prostate gland and benign hypertrophy of prostate/ benign prostatic hyperplasia (BPH).
Transient elevation of PSA levels are seen following digital rectal examination, rigorous physical activity like bicycle riding, ejaculation within
24 hours.
PSA levels tend to increase in all men as they age.
Clinical Utility of PSA:
In the early detection of Prostate cancer.
As an aid in discriminating between Prostate cancer and Benign Prostatic disease.
To detect cancer recurrence or disease progression.
2 0 2
APPROVED BY

MC-3113
Ref. Dr : DR. SELF

HAEMATOLOGY
Complete Blood Count With - ESR
Haemoglobin 14.2 g/dL 13.5 - 18.0

(EDTA Blood/Electrical Impedance)
Packed Cell Volume(PCV)/Haematocrit 42.9 % 42 - 52
(EDTA Blood/Derived from Impedance)
RBC Count 4.76 mill/cu.mm 4.7 - 6.0
(EDTA Blood/Impedance Variation)
Mean Corpuscular Volume(MCV) 90.0 fL 78 - 100
Mean Corpuscular Haemoglobin(MCH) 29.8 pg 27 - 32
Mean Corpuscular Haemoglobin 33.0 g/dL 32 - 36
concentration(MCHC)
RDW-CV 12.0 % 11.5 - 16.0
RDW-SD 37.80 fL 39 - 46
2 0 23
APPROVED BY

MC-3113
Ref. Dr : DR. SELF

Total Leukocyte Count (TC) 7500 cells/cu.mm 4000 - 11000
Neutrophils 50.0 % 40 - 75
(EDTA Blood/Impedance Variation & Flow
Cytometry)
Lymphocytes 38.9 % 20 - 45
Cytometry)
Eosinophils 4.1 % 01 - 06
Cytometry)
Monocytes 6.5 % 02 - 10
Cytometry)
Basophils 0.5 % 00 - 02
(Blood/Impedance Variation & Flow Cytometry)
Absolute Neutrophil count 3.75 10^3 / µl 1.5 - 6.6
Cytometry)
Absolute Lymphocyte Count 2.92 10^3 / µl 1.5 - 3.5
Cytometry)
Absolute Eosinophil Count (AEC) 0.31 10^3 / µl 0.04 - 0.44
Cytometry)
2 0 23
APPROVED BY

MC-3113
Ref. Dr : DR. SELF

Absolute Monocyte Count 0.49 10^3 / µl < 1.0
Cytometry)
Absolute Basophil count 0.04 10^3 / µl < 0.2
Cytometry)
Platelet Count 292 10^3 / µl 150 - 450
MPV 10.2 fL 7.9 - 13.7
PCT 0.30 % 0.18 - 0.28
(EDTA Blood/Automated Blood cell Counter)
ESR (Erythrocyte Sedimentation Rate) 16 mm/hr 0 - 15
(Citrated Blood/Manual Westergren Method)
2 0 23
APPROVED BY

MC-3113
Ref. Dr : DR. SELF

BIOCHEMISTRY
Liver Function Test
Bilirubin(Total) 1.2 mg/dL 0.1 - 1.2

(Serum/Diazotized Sulfanilic Acid)
Bilirubin(Direct) 0.5 mg/dL 0.0 - 0.3
(Serum/Diazotized Sulfanilic Acid)
Bilirubin(Indirect) 0.70 mg/dL 0.1 - 1.0
(Serum/Derived)
Total Protein 7.9 g/dL 6.0 - 8.0
(Serum/Biuret)
Albumin 4.8 g/dL 3.5 - 5.0
(Serum/Bromocresol green)
Globulin 3.10 g/dL 2.3 - 3.5
(Serum/Derived)
A : G Ratio 1.55 1.1 - 2.4
(Serum/Derived)
SGOT/AST (Aspartate Aminotransferase) 14 U/L 5 - 40
(Serum/Modified IFCC without P5P)
SGPT/ALT (Alanine Aminotransferase) 11 U/L 5 - 41
(Serum/Modified IFCC without P5P)
2 0 11
APPROVED BY

MC-3113
Ref. Dr : DR. SELF

Alkaline Phosphatase (SAP) 189 U/L 53 - 128
(Serum/Modified IFCC)
GGT(Gamma Glutamyl Transpeptidase) 25 U/L < 55
(Serum/Modified IFCC)
2 0 11
APPROVED BY

MC-3113
Ref. Dr : DR. SELF

Serum Electrolytes
Sodium 135 mEq/L 135 - 145

(Serum/Ion selective electrode (ISE))
Potassium 4.9 mEq/L 3.5 - 5.5
Chloride 104 mEq/L 95 - 110
2 0 3
APPROVED BY

MC-3113
Ref. Dr : DR. SELF

Lipid Profile
Cholesterol Total 218 mg/dL Optimal: < 200

(Serum/Cholesterol oxidase/Peroxidase) Borderline: 200 - 239
High Risk: >= 240
Triglycerides 161 mg/dL Optimal: < 150

(Serum/Glycerol phosphate oxidase / peroxidase) Borderline: 150 - 199
High: 200 - 499
Very High: >= 500
INTERPRETATION: The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food,
increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal
variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and
screening for metabolic syndrome, as non-fasting sample is more representative of the ³usual´circulating level of triglycerides during most
part of the day.
HDL Cholesterol 55 mg/dL Optimal(Negative Risk Factor): >= 60
(Serum/Immunoinhibition) Borderline: 40 - 59
High Risk: < 40
LDL Cholesterol 130.8 mg/dL Optimal: < 100

(Serum/Derived) Above Optimal: 100 - 129
Borderline: 130 - 159
High: 160 - 189
Very High: >= 190
2 0 8
APPROVED BY

MC-3113
Ref. Dr : DR. SELF

VLDL Cholesterol 32.2 mg/dL < 30
(Serum/Derived)
Non HDL Cholesterol 163.0 mg/dL Optimal: < 130
(Serum/Calculated) Above Optimal: 130 - 159
Borderline High: 160 - 189
High: 190 - 219
Very High: >= 220
INTERPRETATION: 1.Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol.
2.It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a
co-primary target for cholesterol lowering therapy.
Total Cholesterol/HDL Cholesterol Ratio 4 Optimal: < 3.3
(Serum/Calculated) Low Risk: 3.4 - 4.4
Average Risk: 4.5 - 7.1
Moderate Risk: 7.2 - 11.0
High Risk: > 11.0
LDL/HDL Cholesterol Ratio 2.4 Optimal: 0.5 - 3.0

(Serum/Calculated) Borderline: 3.1 - 6.0
High Risk: > 6.0
2 0 8
APPROVED BY

Ref. Dr : DR. SELF

CLINICAL PATHOLOGY
PHYSICAL EXAMINATION
Colour Pale Yellow

(Urine)
Volume 30 mL
(Urine)
Appearance Clear Clear
(Urine)
CHEMICAL EXAMINATION
pH 6.5 4.6 - 8.0

(Urine)
Specific Gravity 1.025 1.003 - 1.030
(Urine)
Protein Trace Negative
(Urine)
Glucose Trace Negative
(Urine)
Ketones Negative Negative
(Urine)
1 1 19
APPROVED BY

Ref. Dr : DR. SELF

Leukocytes Negative Negative
(Urine)
Nitrite Negative Negative
(Urine)
Bilirubin Negative Negative
(Urine)
Blood Negative Negative
(Urine)
Urobilinogen 0.1 mg/dL 0.1 - 1.0
(Urine)
Urine Microscopy Pictures
Pus Cells 2-4 /hpf 0-2

(Urine)
Epithelial Cells 1-2 /hpf 0-2
(Urine)
RBCs Nil /hpf 0-1
(Urine)
Others Nil Nil
(Urine)
Casts Nil 0-1
(Urine)
1 1 19
APPROVED BY

Ref. Dr : DR. SELF

Crystals Nil NIL
(Urine)
*Bacteria Nil
1 1 19
APPROVED BY
-- End of Report --

MC-3113 Ref. Dr : DR. SELF
Investigation Observed Unit Biological

Value Reference Interval
BIOCHEMISTRY
Glycosylated Haemoglobin (HbA1c)
HbA1C 12.1 % Non Diabetic: 4.5 - 5.6

(Whole Blood/HPLC) Pre Diabetes: 5.7 - 6.4
Diabetes: >= 6.5
Good glycemic control: < 7.0
Fair glycemic control: 7.1 - 7.9
Poor glycemic control: >= 8.0
INTERPRETATION: Detection Limit :3.8-18.5%. Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate
deficiency, hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbA1C values.
Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E
ingestion, Pregnancy, End stage Renal disease can cause falsely low HbA1c. HbA1C measurement is not appropriate when there has been a
change in diet or treatment within 6 weeks.
Estimated Average Glucose 300.57 mg/dL 85 - 150
(Blood)
2 0 2
-- End of Report --
Page 1 of 1
VERIFIED BY
APPROVED BY
* Not in NABL scope.

Test/s processed in CLUMAX DIAGNOSTIC & RESEARCH CENTRE PVT LTD.,JAYANAGAR,BENGALURU.
NABL CERTIFICATE No.MC-2271

Biochemistry: Investigation Observed Value Unit Biological Reference Interval

Uploaded by

Copyright:

Available Formats

Biochemistry: Investigation Observed Value Unit Biological Reference Interval

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Biochemistry: Investigation Observed Value Unit Biological Reference Interval

Uploaded by

Copyright:

Available Formats

Name : Mr.

Investigation Observed Value Unit Biological Reference Interval

Glucose Fasting (FBS) 231 mg/dL Normal: <= 100

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

TSH (Thyroid Stimulating Hormone) 4.19 µIU/mL 0.35 - 4.94

INTERPRETATION: Analytical sensitivity: 0.008 - 100 ng/mL

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

Complete Blood Count With - ESR

Haemoglobin 14.2 g/dL 13.5 - 18.0

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

Liver Function Test

Bilirubin(Total) 1.2 mg/dL 0.1 - 1.2

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

Sodium 135 mEq/L 135 - 145

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

Cholesterol Total 218 mg/dL Optimal: < 200

Triglycerides 161 mg/dL Optimal: < 150

LDL Cholesterol 130.8 mg/dL Optimal: < 100

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

LDL/HDL Cholesterol Ratio 2.4 Optimal: 0.5 - 3.0

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

Colour Pale Yellow

pH 6.5 4.6 - 8.0

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

Pus Cells 2-4 /hpf 0-2

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Value Unit Biological Reference Interval

* Represent Those Tests are not in scope of NABL accreditation.

Investigation Observed Unit Biological

Glycosylated Haemoglobin (HbA1c)

HbA1C 12.1 % Non Diabetic: 4.5 - 5.6

* Not in NABL scope.

You might also like